Company intelligence / Profile preview
Emergo Therapeutics
Durham, North Carolina, United Statesemergotherapeutics.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Phase 2
01
Overview
Emergo Therapeutics’ lead program focuses on Norketotifen for the treatment of long COVID and influenza-like illnesses. The company aims to modulate immune response by curtailing the release of inflammation-inducing cytokines without causing immunosuppression. No specific clinical trial results are publicly detailed as of now.
- Therapeutic areas
- ImmunologyInfectious Diseases
- Modalities
- small molecules (notably Norketotifen)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Emergo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Emergo Therapeutics.